In two further studies, assumptions about the cost of the test or re-biopsy did not affect the incremental cost effectiveness of a genotype assay for drug selection in patients with HIV [50] or EML4 (echinoderm microtubule associated protein-like 4)–ALK (anaplastic lymphoma kinase) testing for patients with non-small cell lung cancer [44]. Here, ALK is linked to non-small cell lung carcinoma.